Andrew Kucharchuk
About Andrew Kucharchuk
Andrew Kucharchuk serves as Chief Financial Officer of Chain Bridge I (CBGGF), appointed effective April 1, 2024; the company’s 2025 proxy identifies him as the current CFO for shareholder communications . At appointment he was 43 years old and holds an MBA (Finance) from Tulane University’s Freeman School of Business and is also a graduate of Louisiana State University . Recent SEC filings also show him as an experienced public-company finance executive across multiple issuers, including CFO roles at Cero Therapeutics (since Oct 2024) and Nukkleus (since Jun 2024) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Chain Bridge I (CBGGF) | Chief Financial Officer | Apr 1, 2024 – Present | Not disclosed in company filings |
| Nukkleus Inc. | Chief Financial Officer | Jun 2024 – Present | Not disclosed |
| Cero Therapeutics Holdings, Inc. | Chief Financial Officer | Oct 2024 – Present | Not disclosed |
| Theralink Technologies, Inc. | Chief Financial Officer | May 2023 – Jun 2024 | Not disclosed |
| Adhera Therapeutics, Inc. | CEO (Jul 2020–Sep 2022); COO (Oct 2022–Oct 2023) | 2020 – 2023 | Not disclosed |
| OncBioMune Pharmaceuticals, Inc. | CFO (Nov 2006–Oct 2019); CEO (Nov 2019–Jun 2020) | 2006 – 2020 | Not disclosed |
| Citations: Chain Bridge I CFO role and date and CFO status as of proxy ; Nukkleus CFO ; Cero CFO ; Theralink CFO dates ; Adhera dates ; OncBioMune dates . |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| Windtree Therapeutics, Inc. | Director; Audit Committee Chair | Aug 3, 2025 – Present | Independent director appointment |
| Two Hands Corporation | CFO and Director | Jan 3, 2025 – Feb 20, 2025 | Appointed CFO/Director; resigned Feb 20, 2025 |
| Theralink Technologies, Inc. | Director | Jun 2020 – Present | Board service cited in CFO bio |
| OncBioMune Pharmaceuticals, Inc. | Director | May 28, 2020 – (not specified) | Appointed to board while serving as CEO/CFO |
Fixed Compensation
| Component | Terms | Period | Payer | Amount |
|---|---|---|---|---|
| Company cash compensation (salary/bonus) | “None of our officers or directors has received any cash compensation” prior to an Initial Business Combination | Through proxy record date (2025) | Chain Bridge I | $0 |
| Consulting retainer | Paid upon execution of consulting agreement with sponsor | Apr 2024 | Fulton AC I LLC (controlling shareholder) | $7,500 |
| Consulting fee | Monthly consulting fee during initial term | Apr–Aug 2024 | Fulton AC I LLC | $7,500 per month |
| Discretionary performance bonus eligibility | At Fulton’s sole discretion; not guaranteed | Apr–Aug 2024 | Fulton AC I LLC | Not disclosed |
| Citations: No company cash comp ; Sponsor-paid consulting terms and amounts . |
Performance Compensation
| Incentive Type | Grant Date | Quantity/Strike | Performance Metrics | Payout/Vesting | Status |
|---|---|---|---|---|---|
| Company equity awards (RSUs/PSUs/options) | — | — | — | — | None disclosed; no individual holdings reported |
| Citations: No equity awards or holdings reported for Kucharchuk in the 2025 beneficial ownership table . Company disclosures emphasize no officer cash compensation pre-business combination; no equity awards to officers are described in the proxy . |
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Beneficial ownership (Class A) | None reported for Andrew Kucharchuk as of Sept 11, 2025 |
| Beneficial ownership (Class B/founder shares) | None reported for Andrew Kucharchuk as of Sept 11, 2025 |
| Options/warrants exercisable within 60 days | None reported for Andrew Kucharchuk |
| Ownership as % of shares outstanding | None reported for Andrew Kucharchuk |
| Pledging of company shares | No pledging disclosure; and no shares reported owned |
| Stock ownership guidelines | Not disclosed in proxy filing |
Employment Terms
| Term | Detail |
|---|---|
| Start date in current role | Appointed CFO effective April 1, 2024 |
| Compensation mechanism | Paid via consulting agreement with Fulton AC I LLC (sponsor/controlling shareholder), not by the company; $7,500 upon execution and $7,500/month through Aug 31, 2024; eligible for discretionary performance bonus by Fulton |
| Status as of 2025 proxy | Identified as the Company’s CFO in 2025 proxy Q&A |
| Letter Agreement | Became a party to the existing Letter Agreement (dated Nov 9, 2021) including certain transfer restrictions on company securities |
| Indemnification | Entered into Company’s standard indemnification agreement |
| Severance/change-of-control | Not disclosed in the cited filings |
| Clawback policy | Not disclosed in the cited filings |
| Non-compete/non-solicit | Not disclosed in the cited filings |
Investment Implications
- Alignment: Kucharchuk received no cash compensation from the company pre-business combination, and the proxy shows no equity awarded or owned by him; compensation flowed from the sponsor (Fulton AC) on a short-term consulting basis. This structure materially limits direct pay-for-performance alignment to public shareholders until a business combination and may concentrate incentives around sponsor objectives rather than long-term public TSR or operating metrics .
- Retention risk: The sponsor consulting arrangement was time-bounded (through Aug 31, 2024) with discretionary, non-guaranteed bonus eligibility; absent company-paid salary or long-term equity, retention risk can rise if workloads intensify or timelines extend, though he continued as CFO per the 2025 proxy .
- Governance/related-party optics: Being compensated by the controlling shareholder (Fulton AC) rather than the company introduces perceived related-party dependence; while not inherently adverse, it warrants scrutiny of independence in decision-making leading up to a business combination .
- Ownership/pledging risk: With no reported beneficial ownership, there is no pledging risk, but also minimal “skin in the game” until any post-combination compensation program is adopted .
- Experience and capacity: Concurrent CFO roles (e.g., Cero Therapeutics and Nukkleus) and external directorships demonstrate broad public-company finance expertise, but also signal bandwidth constraints that investors should monitor during critical SPAC execution windows .